Alan B. Lancz & Associates’s GSK GSK Stock Holding History

Alan B. Lancz & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Hold	8,750	–	–	0.4%	68
2026 Q1	$483K	Sell	8,750 -870	-9%	-$47.1K	0.47%	58
2025 Q4	$472K	Hold	9,620	–	–	0.41%	58
2025 Q3	$415K	Sell	9,620 -160	-2%	-$6.25K	0.38%	71
2025 Q2	$376K	Sell	9,780 -720	-7%	-$27.5K	0.38%	71
2025 Q1	$407K	Sell	10,500 -120	-1%	-$4.39K	0.43%	64
2024 Q4	$359K	Sell	10,620 -280	-3%	-$10.1K	0.36%	72
2024 Q3	$446K	Hold	10,900	–	–	0.41%	65
2024 Q2	$420K	Buy	+10,900	New	+$459K	0.41%	63
2023 Q4	$410K	Sell	11,060 -300	-3%	-$10.8K	0.43%	68
2023 Q3	$412K	Sell	11,360 -240	-2%	-$8.52K	0.47%	59
2023 Q2	$413K	Sell	11,600 -80	-0.7%	-$2.87K	0.44%	71
2023 Q1	$416K	Buy	11,680 +1,500	+15%	+$52.5K	0.43%	69
2022 Q4	$360K	Buy	+10,180	New	+$339K	0.36%	88
2022 Q2	–	Sell	-11,860	Closed	-$646K	–	188
2022 Q1	$646K	Hold	11,860	–	–	0.57%	46
2021 Q4	$654K	Buy	+11,860	New	+$617K	0.57%	48

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Alan B. Lancz & Associates's GSK Position: Q2 2026 in Review

Alan B. Lancz & Associates held its GSK (GSK) position steady in Q2 2026 at 8,750 shares worth $459K. The position accounts for 0.4% of the portfolio, ranked #68.

Alan B. Lancz & Associates first reported a position in GSK in Q4 2021 and has held it in 16 quarters since. The position peaked at $654K in Q4 2021. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Alan B. Lancz & Associates held 8,750 shares of GSK worth $459K as of Q2 2026.
Alan B. Lancz & Associates left its GSK share count unchanged in Q2 2026.
GSK made up 0.4% of Alan B. Lancz & Associates's portfolio in Q2 2026, its #68 holding.
Alan B. Lancz & Associates first reported a position in GSK in Q4 2021 and has held it in 16 quarters since.
Alan B. Lancz & Associates's GSK position peaked at $654K in Q4 2021.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.